Trend in Treatment of Acute Ischemic Stroke神經保護組織纖維蛋白溶解原活化劑缺血性中風治療血栓溶解治療急性中風應被視為與心臟病發作其有相同急迫性意識之腦發作。對於急性缺血性中風,用重組組識纖維蛋白溶解原活化劑(rt-PA)進行血栓溶解之治療在美國是被認可的方法。經由一大型的隨機、安慰控制組研究證明,雖然有...
Do not administer Activase to treat acute ischemic stroke in the following situations in which the risk of bleeding is greater than the potential benefit: current intracranial hemorrhage (ICH); subarachnoid hemorrhage; active internal bleeding; recent (within 3 months) intracranial or intraspinal surgery...
The initial therapeutic approach to acute ischemic stroke consists of thrombolytic therapy and early initiation of supportive care, usually commenced prior to the determination of the underlying stroke etiology. Varying stroke mechanisms may call for specific, etiology-based treatment. The majority of str...
Ischemic stroke is a common neurological disease. Currently, there are no Food and Drug Administration-approved drugs that can maximize the improvement in ischemic stroke-induced nerve damage. Hence, treating ischemic stroke remains a clinical challenge. Ferroptosis has been increasingly studied in recent...
Edaravone dexborneol vs edaravone alone for the treatment of acute ischemic stroke: a phase 3, randomized, double-blind, comparative trial. Stroke. 2021;52(3):772-780. doi:10.1161/STROKEAHA.120.031197PubMedGoogle ScholarCrossref 9. Xu J, Wang Y, Wang A, et al. Safety ...
The treatment of acute ischemic stroke has advanced greatly in the last decade. Currently, intravenous tissue plasminogen activator, intra-arterial recombinant pro-urokinase, and mechanical embolectomy have all been shown to be effective in treating acute ischemic stroke patients. This endovascular treat...
Risk factors, pathogenesis, clinical manifestations, diagnosis, and surgical and pharmacological treatment of ischemic stroke are reviewed. Risk factors play an important part in the pathogenesis of ischemic stroke. Knowledge of the complex metabolic and cellular changes that occur during ischemic stroke ...
Recommendations of the European Stroke Initiative (EUSI) for treatment of ischemic stroke. Part 1: Organization and acute therapy I. Organization and acute therapy. Nervenarzt . 2004; 75 (4):368–379.Kulkens S;Ringleb RA;Hacke W;.Recommendations of the European Stroke Initiative (EUSI) for...
The traditional therapeutic goals in the treatment of acute ischemic stroke have been confined to stabilization of the general medical state, prevention of systemic medical complications, and efforts to prevent acute recurrence or progression of stroke (1). By contrast, in this era of rapid medical...
The last decade witnessed significant and unprecedented advances in the treatment of acute ischemic stroke. Intravenous tissue plasminogen activator and defibrinogenating agent are both now approved by the Food and Drug Administration for treatment of acute ischemic stroke within 3 h of symptom onset. ...